Epigenomics AG
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The co…
Medical - Diagnostics & Research
DE, Berlin [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Epigenomics AG's gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | - | -91.912 | - | 1 | - | -78 | - | -1 | - | -1 | - | 11 |
| 2016 | - | -76.588 | - | 4 | - | -65 | - | -3 | - | -4 | - | 27 |
| 2017 | - | -79.790 | - | 1 | - | -68 | - | -1 | - | -1 | - | 8 |
| 2018 | - | -58.004 | - | 1 | - | -49 | - | -1 | - | -1 | - | 11 |
| 2019 | - | -51.232 | - | 1 | - | -43 | - | -1 | - | -1 | - | 8 |
| 2020 | - | -38.983 | - | 0.78 | - | -33 | - | 0.68 | - | 0.69 | - | 4 |
| 2021 | - | -11.537 | - | 7 | - | -9 | - | -6 | - | -6 | - | 42 |
| 2022 | - | -17.836 | - | 0.80 | - | -15 | - | 0.69 | - | 0.70 | - | 4 |
| 2023 | - | -7.231 | - | 1 | - | -6 | - | -1 | - | -1 | - | 10 |
| 2024 | - | -0.447 | - | 0.33 | - | 0.38 | - | 0.28 | - | 0.29 | - | 1 |
| 2025 | - | -0.755 | - | 0.26 | - | 0.64 | - | 0.23 | - | 0.23 | - | 1 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
Nov. 6, 2024Price Then
$0.79
Price Target
$n/a
Price Now
$0.79